Knowledge of fetal HLA type can be important if cord blood (CB) is being considered as a stem cell source for transplantation. The feasibility of determining the paternally inherited HLA haplotype of a fetus was explored through analysis of fetal DNA in the maternal circulation. A 5-year-old child with relapsed acute leukemia was a candidate for transplantation. The HLA type of the fetal sibling was needed to assist with evaluation of this potential cord blood donor. DNA was isolated from maternal plasma and whole blood. Kinetic PCR using sequence-specific primers for paternal HLA-A, -B, and -DRB1 alleles was performed. Alleles corresponding to one paternal haplotype were detectable in plasma, but not in whole blood. Alleles from the alternative haplotype were not detectable. This demonstrated that the fetus shared at least one haplotype with the patient and therefore arrangements were made to bank the CB. The maternal haplotype of the fetus could not be determined in the presence of maternal DNA. The prenatal fetal typing was confirmed by typing the newborn's CB. This rapid non-invasive technique may facilitate the selection of CB units for banking based on needed HLA types. Bone Marrow Transplantation (2002) 29, 527-529. DOI: 10.1038/sj/bmt/1703411 Keywords: prenatal HLA typing; prenatal diagnosis; real-time PCR; kinetic PCR; cord blood; transplantation; microchimerism Determination of the fetal HLA type can be clinically important, particularly where CB from a current pregnancy is being considered for banking or transplantation.
invasively using both cell-associated and cell-free fetal DNA which enters the mother's circulation during pregnancy. Analysis of fetal DNA in maternal plasma has allowed noninvasive prenatal determination of fetal Rh D genotype, 3 and is promising in other conditions. 4 We describe the first noninvasive determination of a paternally inherited fetal HLA haplotype and the use of kinetic PCR to detect fetal DNA in maternal plasma during late third trimester. Non-invasive prenatal HLA typing will be useful for evaluation of CB for transplantation of a family member or banking.
Materials, patients and methods

Case report
A 5-year-old female with acute leukemia had initial therapy in Mexico. The family relocated to the United States and presented for care at the time of leukemic relapse. Chemotherapy induced a second remission, but the high likelihood of relapse made immediate allogeneic transplantation the preferred treatment. If the fetus were known to be HLAmismatched, transplant from an alternative donor could be pursued immediately. The mother was 36 weeks pregnant with a full sibling to the patient.
Family HLA typing
HLA typing HLA-A, -B, -C and -DRB1 alleles of the patient, mother and father were determined by automated sequencing of selectively amplified HLA loci or alleles (Figure 1 ). After birth, HLA-A, -B, and DRB1 types of CB were similarly determined by automated sequencing.
Prenatal HLA typing of maternal blood by kinetic PCR
Following approval of the Committee on Human Research at the University of California San Francisco, informed consent for this investigation was obtained from the mother.
Maternal blood was collected in EDTA anticoagulant and DNA was extracted from whole blood or plasma using spin columns containing a silica-gel membrane (Qiagen, Valencia, CA, USA). DNA was isolated from whole blood and resuspended in DNA buffer (10 mm Tris-base, 2. lents (gEq)/l. DNA isolated from 200 l plasma was resuspended in 100 l DNA buffer. Each PCR reaction contained 5 l of DNA template, 10 l of 2 ϫ PCR buffer [40 mm Tris-HCl, 100 g/ml BSA, 0.2% (v/v) Triton X 100, 15 mm KCl, 1 mm each dNTP, 4 mm MgCl 2 , 1 m forward primer, 1 m reverse primer, 1:100 000 SYBR Green (Sigma, St Louis, MO, USA), and 0.7 unit AmpliTaq Gold (PE Biosystems, Foster City, CA, USA)] with 10 l mineral oil (Sigma) added as a vapor barrier. Primers for amplification of HLA-DRB1 alleles were described previously. 5 Forward (F) and reverse (R) primer sequences for class I HLA alleles were: A29F AGGATGGAGCCGCGGGCA, A29R TTCACATTC CGTGTCTGCA, B44F GGCCAGGGTCTCACATCA, B44R CCAGGTATCTGCGGAGCG, A2F CCCGTCCCAA TACTCCGGA, A2R GGAGCCCCGCTTCATCGCA, B58F ACGCCGCGAGTCCGAGAGA, B58R TGTAGATCTGT GTGTTCCG. The PCR reaction tubes were sealed with optical cover tape, heated for 10 min at 95°C. Amplification was carried out for 50 cycles with denaturation for 30 s at 95°C, annealing for 30 s at 64°C, and elongation for 45 s at 72°C (GeneAmp 5700, PE Biosystems).
Results
HLA-A, -B, -C, and -DRB1 types of the patient and both parents were determined and haplotypes were deduced (Figure 1 ). Because HLA types were not shared between the parents, the inheritance of HLA haplotypes was fully informative. For assays performed using DNA isolated from maternal plasma, sequence-specific kPCR detected paternal HLA types HLA-A29, -B44, and -DRB1*07, while HLA-A2, -B58, and -DRB1*03 were not detectable ( Figure  2) . No paternal HLA alleles could be detected in DNA isolated from maternal whole blood.
Maternal HLA alleles were also detectable in maternal plasma. However, the maternal allele inherited by the fetus could not be determined because it was identical to this maternal background DNA.
Because the CB was anticipated to be at least a haplotype match, specific arrangements were made for collection and cryopreservation of the CB at delivery. DNA-based typing performed on the CB after delivery confirmed the paternal haplotype inheritance predicted by the non-invasive typing of maternal plasma. However, complete typing also showed that the maternal haplotype was mismatched. The unrelated bone marrow donor was the best remaining option, however the child relapsed again and died before any transplant option could be arranged.
Discussion
These data demonstrate that during late third trimester, the paternal HLA haplotype inherited by the fetus could be Figure 2 Representative kPCR data for paternal HLA-B44 in maternal plasma. SYBR green fluorescence, indicative of a double-stranded PCR product, is plotted on the y-axis as a function of amplification cycle number on the x-axis. The upper panel shows results for standard dilutions of HLA-B44; a single copy of template produces fluorescent signal after approximately 36 cycles of amplification. The lower panel depicts results from four plasma replicates and two negative (no-template) controls. Three of the four plasma replicates had a positive signal at endpoint sensitivity (single copy), while one plasma sample and negative controls remained negative through 49 cycles. Since the three positive reactions have only one copy of HLA-B44 and one of the four replicates was negative, it is likely that given expected distribution, the HLA-B44 target sequence was not present in one of the four aliquots. Negative observations may be prevented by increasing the total amount of DNA in each reaction. detected in maternal plasma and was identical to that inherited by the patient. Levels of maternal DNA in the plasma were too high to detect any incremental increase contributed by the maternal types inherited by the fetus. These prenatal typing results were confirmed by HLA typing of CB obtained after delivery using DNA sequencing. More generally, these data show that the sensitivity of kPCR is sufficient to provide rapid analysis of the paternally inherited haplotype fetal DNA in the maternal plasma late in the third trimester.
The inability to detect paternal HLA types in DNA isolated from whole blood was expected and probably reflects the extreme rarity of the target sequence in the cell-associated fraction. Although kinetic PCR provided single copy sensitivity, the total amount of DNA in each reaction tube limits detectability. Thus, if each tube contains 25 000 genome equivalents, the target sequence must be present at Ͼ1:25 000 for detection. It is unlikely that competition for primer by maternal DNA reduced sensitivity, 6 because kPCR using allele-specific primers can routinely detect a single copy of an HLA gene in a background of Ͼ25 000 genome equivalents of non-target genes (unpublished observations).
Plasma DNA may be preferable to fetal cellular DNA as a diagnostic specimen in some situations. In most noninvasive prenatal diagnoses, enrichment of fetal cells from maternal blood has been required. There are several difficulties associated with this strategy. Fetal nucleated cells are rare compared with maternal nucleated cells and complex procedures are usually required to achieve sufficient enrichment of these cells from maternal blood. Fetal leukocytes can also persist in the maternal circulation for years and perhaps decades following parturition, 7 raising the possibility that a prenatal diagnosis might inadvertently be based on cells derived from a previous pregnancy. To simplify and speed the analysis, this investigation took advantage of recent observations from our group 8 and others 9 that fetal DNA is more abundant in maternal plasma than in the cellular compartment and that its ratio to maternal DNA is greater in plasma. The source of this fetal DNA has not been definitively demonstrated, but its rapid clearance following parturition (t . = hours) 10 suggests that the process is extremely dynamic and therefore fetal plasma DNA is unlikely to persist from a previous pregnancy. The increase in relative levels of fetal DNA in plasma that has been observed previously is consistent with this investigation which shows that kPCR can detect genes unique to fetal DNA in maternal plasma, but not whole blood.
One limitation of this methodology is that it is restricted to informative genetic markers which are absent in the mother, ie the background genotype must not contain the target polymorphism. For prenatal HLA typing, determination of the maternally inherited HLA haplotype is precluded unless enrichment of fetal genetic material precedes the analysis. Despite this limitation, this comparatively rapid technique may provide important information needed to support urgent clinical decisions regarding the evaluation of alternative stem cell sources. The technique may prove useful in the general setting of sibling donor CB bankBone Marrow Transplantation ing, 11, 12 because cord blood that is known not to be suitable for transplantation of a sibling could be excluded from banking.
This technology suggests a method for preselection of unrelated donor CB for banking based upon HLA typing. Results, if they could be obtained reliably and cost-effectively, might also be applied to exclude banking of unrelated donor CBs shown prenatally to contain certain common HLA types. More investigation is needed to determine assay performance characteristics and whether the technique would yield useful results earlier in pregnancy.
